Compare
Side by side
Pick up to three peptides to see how their mechanisms, studied uses and evidence levels differ. Rows where the entries disagree are marked with a blue edge.
Selected 1 of 3
Comparison
N-Acetyl Semax amidate
Cognitive & neuro
Evidence level
Anecdotal evidence
Approval status
Not approved
Mechanism of action
- 1.The ACTH(4-7) core carries melanocortin-type signalling into the brain without stimulating steroid production.
- 2.Animal studies report increased BDNF and NGF expression in the hippocampus.
- 3.Reported modulation of dopaminergic and serotonergic transmission in rodent models.
- 4.The Pro-Gly-Pro tail is thought to slow peptidase breakdown.
- 5.The acetyl and amide caps are intended to resist exopeptidase digestion at both ends.
Studied for
- Animal models of ischaemic stroke and brain injury
- Rodent tests of attention, memory and anxiety
- Comparison with unmodified Semax in Russian literature
Reported effects
- No established human effects for the acetylated, amidated form
- Reported cognitive changes come from user reports, not controlled trials
- Purity and identity of grey-market product are unverifiable
Side effects
- Not established in humans
- Nasal irritation with intranasal use
- Theoretical melanocortin effects such as appetite or skin pigmentation change
- Unknown interactions and purity risks
Research protocol
Research context only - there is no approved human protocol for this modified peptide. Animal work used microgram to milligram per kilogram doses, often intranasally, over days. Human intranasal Semax data come from Russian studies of the unmodified 0.1% solution, which the acetylated amidated variant has never been through.
Research context only
Evidence justification
No controlled human trials of the modified peptide exist; the evidence is animal work on related molecules plus uncontrolled user reports.